Cognoptix Revenue and Competitors
Estimated Revenue & Valuation
- Cognoptix's estimated annual revenue is currently $1.3M per year.
- Cognoptix's estimated revenue per employee is $251,000
Employee Data
- Cognoptix has 5 Employees.
- Cognoptix grew their employee count by 0% last year.
Cognoptix's People
| Name | Title | Email/Phone |
|---|
Cognoptix Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $9.8M | 39 | 3% | N/A | N/A |
#2 | $8.5M | 34 | 3% | N/A | N/A |
#3 | $3M | 12 | -29% | N/A | N/A |
#4 | $5630M | 7477 | -11% | $450M | N/A |
#5 | $4.5M | 18 | 6% | N/A | N/A |
#6 | $7.2M | 57 | 27% | $29.6M | N/A |
#7 | $14.3M | 57 | -12% | N/A | N/A |
#8 | $2.3M | 18 | 6% | $44M | N/A |
#9 | $40.7M | 162 | -1% | N/A | N/A |
#10 | $45.7M | 182 | -5% | N/A | N/A |
What Is Cognoptix?
Cognoptix is a late stage, point-of-care diagnostic company committed its breakthrough technology system, Sapphire II, for the early detection and diagnosis of Alzheimer's disease (AD). Sapphire II is an inexpensive, non-invasive method that detects amyloid deposits in the brain through imaging the ocular lens of the eye. Amyloid is the earliest detectable biomarker of AD, observed aggregating in the brain up to 20 before the symptomatic onset of AD. AD estimated to affect 20 million patients, costing $1 trillion in care by 2050.
keywords:N/A
N/A
Total Funding
5
Number of Employees
$1.3M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Marlborough
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.4M | 5 | 0% | N/A |
#2 | $0.4M | 5 | 0% | N/A |
#3 | $0.4M | 6 | -14% | N/A |
#4 | $0.6M | 8 | -11% | N/A |
#5 | $0.6M | 8 | -20% | N/A |